Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | APLT |
---|---|---|
09:32 ET | 6173 | 4.4 |
09:36 ET | 100 | 4.43 |
09:38 ET | 1500 | 4.425 |
09:39 ET | 3130 | 4.42 |
09:41 ET | 800 | 4.4 |
09:43 ET | 2648 | 4.41 |
09:45 ET | 900 | 4.41 |
09:48 ET | 3925 | 4.37 |
09:50 ET | 3002 | 4.37 |
09:52 ET | 800 | 4.37 |
09:54 ET | 17548 | 4.4 |
09:56 ET | 2072 | 4.373 |
09:59 ET | 642 | 4.3659 |
10:01 ET | 100 | 4.355 |
10:03 ET | 900 | 4.33 |
10:06 ET | 300 | 4.33 |
10:08 ET | 2482 | 4.32 |
10:10 ET | 1600 | 4.31 |
10:12 ET | 1037 | 4.325 |
10:14 ET | 5541 | 4.31 |
10:15 ET | 600 | 4.312 |
10:19 ET | 15177 | 4.36 |
10:21 ET | 300 | 4.355 |
10:26 ET | 100 | 4.355 |
10:28 ET | 200 | 4.355 |
10:30 ET | 2196 | 4.33 |
10:32 ET | 3314 | 4.31 |
10:33 ET | 5834 | 4.335 |
10:35 ET | 425 | 4.3286 |
10:37 ET | 250 | 4.35 |
10:42 ET | 3862 | 4.355 |
10:44 ET | 100 | 4.355 |
10:46 ET | 600 | 4.35 |
10:48 ET | 2648 | 4.33 |
10:51 ET | 700 | 4.31 |
10:53 ET | 300 | 4.31 |
10:55 ET | 6420 | 4.34 |
10:57 ET | 5836 | 4.35 |
11:00 ET | 302 | 4.36 |
11:02 ET | 1325 | 4.35 |
11:06 ET | 400 | 4.31 |
11:08 ET | 400 | 4.31 |
11:09 ET | 4025 | 4.34 |
11:13 ET | 1151 | 4.33 |
11:15 ET | 1100 | 4.33 |
11:18 ET | 2697 | 4.35 |
11:26 ET | 100 | 4.34 |
11:27 ET | 4072 | 4.35 |
11:29 ET | 100 | 4.36 |
11:31 ET | 1250 | 4.35 |
11:33 ET | 2690 | 4.35 |
11:36 ET | 2717 | 4.35 |
11:38 ET | 600 | 4.33 |
11:40 ET | 1200 | 4.32 |
11:42 ET | 6624 | 4.34 |
11:44 ET | 1275 | 4.32 |
11:45 ET | 3323 | 4.335 |
11:47 ET | 500 | 4.335 |
11:49 ET | 852 | 4.33 |
11:51 ET | 100 | 4.33 |
11:54 ET | 3113 | 4.33 |
11:56 ET | 1221 | 4.32 |
11:58 ET | 1625 | 4.33 |
12:00 ET | 4500 | 4.315 |
12:02 ET | 400 | 4.31 |
12:03 ET | 200 | 4.315 |
12:05 ET | 100 | 4.31 |
12:07 ET | 15913 | 4.29 |
12:09 ET | 8231 | 4.32 |
12:12 ET | 100 | 4.32 |
12:16 ET | 100 | 4.32 |
12:18 ET | 10024 | 4.355 |
12:21 ET | 15140 | 4.35 |
12:23 ET | 300 | 4.34 |
12:25 ET | 2695 | 4.35 |
12:27 ET | 100 | 4.35 |
12:30 ET | 300 | 4.35 |
12:32 ET | 1338 | 4.35 |
12:34 ET | 200 | 4.34 |
12:36 ET | 1900 | 4.36 |
12:38 ET | 3026 | 4.35 |
12:39 ET | 1400 | 4.355 |
12:41 ET | 1920 | 4.35 |
12:43 ET | 828 | 4.345 |
12:45 ET | 443 | 4.35 |
12:48 ET | 300 | 4.34 |
12:50 ET | 900 | 4.34 |
12:52 ET | 7107 | 4.35 |
12:54 ET | 109 | 4.355 |
12:56 ET | 722 | 4.36 |
12:57 ET | 527 | 4.36 |
12:59 ET | 2577 | 4.35 |
01:01 ET | 216 | 4.35 |
01:03 ET | 600 | 4.35 |
01:06 ET | 3872 | 4.35 |
01:08 ET | 200 | 4.33 |
01:10 ET | 1400 | 4.35 |
01:12 ET | 1063 | 4.34 |
01:14 ET | 200 | 4.33 |
01:15 ET | 5185 | 4.34 |
01:21 ET | 100 | 4.35 |
01:24 ET | 670 | 4.345 |
01:26 ET | 2582 | 4.35 |
01:28 ET | 1460 | 4.37 |
01:30 ET | 100 | 4.365 |
01:32 ET | 1700 | 4.36 |
01:33 ET | 550 | 4.355 |
01:35 ET | 600 | 4.35 |
01:37 ET | 2219 | 4.354 |
01:39 ET | 4794 | 4.35 |
01:42 ET | 425 | 4.37 |
01:46 ET | 200 | 4.36 |
01:48 ET | 3948 | 4.35 |
01:50 ET | 214 | 4.345 |
01:51 ET | 638 | 4.34 |
01:53 ET | 436 | 4.34 |
01:55 ET | 7663 | 4.35 |
01:57 ET | 514 | 4.35 |
02:00 ET | 725 | 4.35 |
02:02 ET | 625 | 4.34 |
02:06 ET | 1225 | 4.35 |
02:08 ET | 27799 | 4.35 |
02:09 ET | 2069 | 4.37 |
02:13 ET | 2850 | 4.38 |
02:15 ET | 1453 | 4.41 |
02:18 ET | 2725 | 4.42 |
02:20 ET | 3654 | 4.44 |
02:22 ET | 2344 | 4.44 |
02:24 ET | 435 | 4.44 |
02:26 ET | 645 | 4.44 |
02:27 ET | 1187 | 4.44 |
02:29 ET | 626 | 4.43 |
02:31 ET | 4253 | 4.47 |
02:33 ET | 924 | 4.46 |
02:36 ET | 5182 | 4.46 |
02:38 ET | 326 | 4.47 |
02:40 ET | 896 | 4.46 |
02:42 ET | 2642 | 4.435 |
02:44 ET | 222 | 4.43 |
02:45 ET | 1148 | 4.43 |
02:47 ET | 726 | 4.42 |
02:49 ET | 431 | 4.425 |
02:51 ET | 443 | 4.42 |
02:54 ET | 734 | 4.42 |
02:56 ET | 831 | 4.4 |
02:58 ET | 5357 | 4.425 |
03:00 ET | 440 | 4.425 |
03:02 ET | 17188 | 4.385 |
03:03 ET | 3408 | 4.4 |
03:05 ET | 644 | 4.385 |
03:07 ET | 2593 | 4.395 |
03:09 ET | 327 | 4.395 |
03:12 ET | 478 | 4.395 |
03:14 ET | 454 | 4.395 |
03:16 ET | 2048 | 4.39 |
03:18 ET | 669 | 4.385 |
03:20 ET | 5467 | 4.395 |
03:21 ET | 1130 | 4.38 |
03:23 ET | 200 | 4.37 |
03:25 ET | 500 | 4.38 |
03:27 ET | 7297 | 4.375 |
03:30 ET | 409 | 4.38 |
03:32 ET | 3939 | 4.35 |
03:34 ET | 10994 | 4.345 |
03:36 ET | 100 | 4.35 |
03:38 ET | 5331 | 4.34 |
03:39 ET | 1066 | 4.335 |
03:41 ET | 2082 | 4.335 |
03:43 ET | 7627 | 4.325 |
03:45 ET | 3761 | 4.325 |
03:48 ET | 10016 | 4.34 |
03:50 ET | 11603 | 4.35 |
03:52 ET | 4819 | 4.335 |
03:54 ET | 10041 | 4.345 |
03:56 ET | 17215 | 4.295 |
03:57 ET | 7470 | 4.28 |
03:59 ET | 23043 | 4.28 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Applied Therapeutics Inc | 489.1M | -2.2x | --- |
Absci Corp | 476.1M | -3.6x | --- |
Fulcrum Therapeutics Inc | 487.9M | -4.9x | --- |
IGM Biosciences Inc | 491.7M | -1.9x | --- |
Verve Therapeutics Inc | 435.8M | -1.8x | --- |
Neurogene Inc | 488.1M | -8.2x | --- |
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $489.1M |
---|---|
Revenue (TTM) | $-477.0K |
Shares Outstanding | 114.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.89 |
EPS | $-1.91 |
Book Value | $-0.20 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.